Download our Application Note “Isogenica’s PD-L1 VHH as Functional Antagonists”
Interested in the potential of antagonist/agonist VHH antibodies in treating diseases? Download our application note “PD-L1 VHH as Functional Antagonists”
Abstract:
VHH AS AN ATTRACTIVE ALTERNATIVE FOR TARGETING PD-L1
VHH can be engineered to tune their binding selectivity and specificity for antigen targeting whilst their favourable
biophysical properties simplify development and manufacturing. Due to their small size and biophysical robustness,
VHH single domain antibodies are ideally suited for targeting tumour-associated antigens such PD-L1, as they can be
incorporated into a number of therapeutic formats.
Who should read this:?
- Researchers in antibody discovery, engineering and development
- Thought leaders in antibody development
Note: It is our responsibility to protect your privacy and we guarantee that your data will be completely confidential.
